破裂脑动静脉畸形急性靶向栓塞的安全性与血管构筑变化
急性靶向栓塞对再破裂率有显著保护作用(年风险1.2% vs 4.3%,p=0.025),且不增加并发症,但需连续影像随访监测畸形团演变。
要点
- 急性靶向栓塞血管造影薄弱点(尤其动脉瘤)在破裂bAVM早期恢复阶段技术安全。
- 急性靶向治疗显著降低再破裂率(年风险1.2% vs 4.3%,p=0.025)。
- 急性靶向栓塞后需连续影像随访以监测畸形团自发复发或消退。
核心结论
- 急性靶向栓塞血管造影薄弱点(尤其动脉瘤)在破裂bAVM早期恢复阶段技术安全且具有保护作用。
研究设计与样本
- 比较急性栓塞与延迟管理的临床和功能结局。
- 比较急性栓塞与有血管造影靶点但未急性栓塞患者的结局。
- 20例患者有栓塞后即刻及6周内随访血管造影以评估血管构筑变化。
主要发现
- 总死亡率0.9%(3例死亡),总体再破裂率每年4.8%。
- 急性栓塞与延迟管理组在人口学变量、死亡率和再破裂率上无统计学差异。
- 急性栓塞组功能更差(mRS 0-2分:46.9% vs 69.8%,p=0.018)且更需辅助治疗(71.9% vs 26.4%,p<0.001)。
- 急性靶向治疗对再破裂率有显著保护作用(年风险1.2% vs 4.3%,p=0.025),治疗并发症无差异。
- 多变量分析预测急性靶向治疗再破裂更低,伴动脉瘤、深静脉解剖和较高Spetzler-Martin分级再破裂更高。
关键数值与推荐
- 急性靶向栓塞组再破裂年风险1.2%,非急性栓塞靶点组4.3%(p=0.025)。
- 急性栓塞组mRS 0-2分比例46.9%,延迟管理组69.8%(p=0.018)。
- 急性栓塞组需辅助治疗比例71.9%,延迟管理组26.4%(p<0.001)。
- 所有急性栓塞患者血管造影薄弱点完全闭塞,畸形团不同程度消退,无新薄弱点出现。
临床怎么用
- 对破裂bAVM的血管造影薄弱点(尤其动脉瘤)可考虑急性靶向栓塞以降低早期再破裂风险。
- 急性靶向栓塞后应进行连续影像随访,监测畸形团自发复发或消退。
- 伴动脉瘤、深静脉解剖或高Spetzler-Martin分级者再破裂风险较高,需更密切监测。
局限性
- 回顾性研究设计。
- 需要更大规模前瞻性研究验证 findings。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to 1) compare the safety and efficacy of acute targeted embolization of angiographic weak points in ruptured brain arteriovenous malformations (bAVMs) versus delayed treatment, and 2) explore the angioarchitectural changes that follow this intervention. METHODS: The authors conducted a retrospective analysis of a prospectively acquired database of ruptured bAVMs. Three hundred sixteen patients with ruptured bAVMs who presented to the hospital within 48 hours of ictus were included in the analysis. The first analysis compared clinical and functional outcomes of acutely embolized patients to those with delayed management paradigms. The second analysis compared these outcomes of patients with acute embolization to those with angiographic targets who did not undergo acute embolization. Finally, a subset of 20 patients with immediate postembolization angiograms and follow-up angiograms within 6 weeks of treatment were studied to determine the angioarchitectural changes after acute targeted embolization. Kaplan-Meier curves for survival between the groups were devised. Multivariate logistical regression analysis was conducted. RESULTS: There were three deaths (0.9%) and an overall rerupture rate of 4.8% per year. There was no statistical difference in demographic variables, mortality, and rerupture rate between patients with acute embolization and those with delayed management. Patients with acute embolization were more likely to present functionally worse (46.9% vs 69.8%, modified Rankin Scale score 0-2, p = 0.018) and to require an adjuvant therapy (71.9% vs 26.4%, p < 0.001). When comparing acutely embolized patients to those nonacutely embolized angiographic targets, there was a significant protective effect of acute targeted therapy on rerupture rate (annual risk 1.2% vs 4.3%, p = 0.025) and no difference in treatment complications. Differences in the survival curves for rerupture were statistically significant. Multivariate analyses significantly predicted lower rerupture in acute targeted treatment and higher rerupture in those with associated aneurysms, deep venous anatomy, and higher Spetzler-Martin grade. All patients with acute embolization experienced complete obliteration of the angiographic weak point with various degrees of resolution of the nidus; however, some had spontaneous recurrence of their bAVM, while others had spontaneous resolution over time. No patients developed new angiographic weak points. CONCLUSIONS: This study demonstrates that acute targeted embolization of angiographic weak points, particularly aneurysms, is technically safe and protective in the early phase of recovery from ruptured bAVMs. Serial follow-up imaging is necessary to monitor the evolution of the nidus after targeted and definitive treatments. Larger prospective studies are needed to validate these findings.
引用
- Mansur A, Kostynskyy A, Krings T, et al. The safety profile and angioarchitectural changes after acute targeted embolization of ruptured arteriovenous malformations. J Neurosurg. 2021. PMID: 33962377. doi:10.3171/2020.9.JNS201558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。